Self-balancing Personal Exoskeleton for SCI (Site 2)
Launched by WANDERCRAFT · Feb 6, 2025
Trial Information
Current as of August 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a personal exoskeleton, a type of wearable robotic device, to see how safe and effective it is for people with spinal cord injuries (SCI), including those with paraplegia (paralyzed from the waist down) and tetraplegia (paralyzed from the neck down). The goal is to help individuals regain some movement and independence. The study is currently looking for participants aged 18 and older who have had a spinal cord injury for at least six months and can attend 9 to 10 training and assessment visits at a research center.
To take part in this trial, participants need to be able to understand and sign consent forms, live in the U.S., and speak English. They should not have other severe health conditions or complications that could interfere with using the exoskeleton. If eligible, participants will engage in training sessions to learn how to use the exoskeleton effectively. This study could provide new insights into helping people with spinal cord injuries improve their mobility and overall quality of life.
Gender
ALL
Eligibility criteria
- SCI user inclusion Criteria:
- • Any gender, age 18 years or older;
- • Motor complete or incomplete SCI with lesions at or above T6;
- • ≥ 6 months post SCI;
- • Able and willing to attend 9 to 10 visits1 to the center, including sessions of training and assessments of one-to-three hours duration;
- • Able to read, understand, and provide informed consent;
- • Living in the US and speaks English.
- SCI user exclusion Criteria:
- • Diagnosis of neurological injury other than SCI;
- • Progressive condition that would be expected to result in changing neurological status;
- • Severe concurrent medical disease, illness or condition judged to be contraindicated by the site physician;
- • Unhealed or unstable traumatic or high impact lower extremity fracture of any duration that is, in the clinical judgement of the study physician, exclusionary for standing and walking;
- • Knee (proximal tibia and/or distal femur) BMD \<0.60 gm/cm2;
- • Total hip BMD T-scores \< -3.5;
- • Fragility, minimal trauma, or low impact fracture of the lower extremity since SCI;
- • Untreatable severe spasticity judged to be contraindicated by the site physician;
- • Untreated/uncontrolled hypertension, as judged to be contraindicated by the site physician;
- • Unresolved orthostatic hypotension (change from baseline seated BP to a fall in 20mmHg SBP and/or fall in 10mmHG DBP and symptoms when standing), or as judged to be contraindicated by the site physician;
- • Open or unhealed skin pressure sores, abrasions, or bruises at any of the contact points of the exoskeleton;
- • Morphological contraindications to the use of the device;
- • Uncorrectable leg length discrepancy over 2 cm (about 0.79 in) when using additional correction tools;
- • Unable to effectively operate the device with a hand-control interface, due to functional and/or cognitive impairment, evaluated based on the ability to manipulate the joystick in all direction, press and identify buttons on the hand control interface.
- • Improper fitting in the device;
- • Psychopathology documentation in the medical record that may conflict with study objectives;
- • Pregnancy or women who plan to become pregnant during the study period;
- • Concurrent participation in another interventional trial;
- • History of uncontrolled autonomic dysreflexia;
- • Presence colostomy and/or urostomy;
- • Ventilator use at the time of the exoskeleton use;
- • Insufficient strength and performance capability (the ability to transfer into/out of the device or perform other training tasks with assistance).
- Companion inclusion Criteria:
- • Any gender, age 18 years or older;
- • Willingness to attend 9 to 10 visits to the center, including sessions of training and assessments of one-to-three hours duration with the SCI user;
- • Able to read, understand and provide informed consent;
- • Living in the US and speaks English.
- Companion exclusion Criteria:
- • Inability to communicate with an assistant due to cognitive and language disorders;
- • Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol- specified assessments;
- • Insufficient strength and performance capability, evidenced by the ability to hold and retain the device in case of unbalance/fall;
- • Insufficient availability to complete the study;
- • Concurrent participation in another interventional trial.
About Wandercraft
Wandercraft is an innovative clinical trial sponsor dedicated to advancing rehabilitation technologies through the development of exoskeleton solutions. With a focus on improving mobility and enhancing the quality of life for individuals with mobility impairments, Wandercraft leverages cutting-edge robotics and artificial intelligence to create adaptive, user-friendly devices. Their commitment to rigorous clinical research ensures that their products are not only effective but also safe, paving the way for transformative therapies in the field of physical rehabilitation. Through collaboration with healthcare professionals and research institutions, Wandercraft aims to redefine the standards of care for patients recovering from neurological and musculoskeletal conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
West Orange, New Jersey, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported